

amended sheet

WO00/27425

(NEW) CLAIMS:

Sub
A
09501680-010902

1. A pharmaceutical preparation for the treatment of blood coagulation disorders containing at least one pro-protein of blood coagulation, selected from the group of factor VIII, von Willebrand factor (vWF) or factor V, and, in addition, a coagulation physiologically inert receptor binding competitor selected from the group of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin.

2. A preparation according to claim 1, characterized in that said pro-protein is derived from a biological material selected from the group of human plasma, a plasma fraction and a cell culture supernatant.

3. A preparation according to claim 1 or 2, characterized in that it is provided as a set containing

- a) said pro-protein of blood coagulation and
- b) said receptor binding competitor.

4. A preparation according to any one of claims 1 to 3, characterized in that said pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture of aprotinin and tPA.

5. A preparation according to any one of claims 1 to 3, characterized in that said pro-protein of blood coagulation is vWF and said receptor binding competitor is a mixture of aprotinin and tPA.

6. A combination preparation containing aprotinin and tPA for medical use.

Sub
A2
7. The use of a preparation according to any one of claims 1 to 5 for the preparation of a means to treat a patient suffering from phenotypic coagulation factor deficiency.

8. The use according to claim 7, characterized in that said patient is vWF deficient.

Sub
A3
9. The use of a preparation according to any one of claims 1 to 5 for the preparation of a means to extend the biological *in vivo* half-life of said protein.

10. The use of a preparation according to claim 9 containing aprotinin and tPA.

amended sheet

WO00/27425

Sub
Q3
cont

11. The use according to claim ~~9~~ characterized in that said protein is blood

coagulation factor VIII.

12. The use of a pharmaceutical preparation containing a coagulation physiologically inert receptor binding competitor selected from the group of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin to extend the biological half-life of a protein selected from the group of factor VIII, factor V and vWF.

09031680-010902